Mepo for Eosinophilic Esophagitis (EoE) Study

NCT03656380 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

66

Enrollment

OTHER

Sponsor class

Conditions

EoE
Eosinophilic Esophagitis

Interventions

DRUG: Mepolizumab 300 mg
DRUG: Mepolizumab 100 mg
OTHER: Placebo

Sponsor

University of North Carolina, Chapel Hill

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]